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Tumour progression in neuroblastoma (NB) patients correlates with high vascular index. We have previously shown that the ACN
NB cell line is tumorigenic and angiogenic in immunodeficient mice, and that interferon-g (IFN-g) gene transfer dampens ACN
tumorigenicity. As IFN-g represses lymphocyte-induced tumour angiogenesis in various murine models and inhibits proliferation and
migration of human endothelial cells, we have investigated the antiangiogenic activity of tumour-derived IFN-g and the underlying
mechanism(s). In addition, we characterised the tumour vasculature of the ACN xenografts, using the chick embryo chorioallantoic
membrane assay. We show that the ACN/IFN-g xenografts had a lower microvessel density and less in vivo angiogenic potential than
the vector-transfected ACN/neo. The vascular channels of both xenografts were formed by a mixed endothelial cell population of
murine and human origin, as assessed by the FICTION (fluorescence immunophenotyping and interphase cytogenetics) technique.
With respect to ACN/neo, the ACN/IFN-g xenografts showed more terminal deoxynucleotidyl transferase-mediated dUTP nick end
labelling-positive human and murine endothelial cells, suggesting that inhibition of angiogenesis by IFN-g was dependent on the
induction of apoptosis, likely mediated by nitric oxide. Once the dual origin of tumour vasculature is confirmed in NB patients, the
xenograft model described here will prove useful in testing the efficacy of different antiangiogenic compounds.
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Neuroblastoma (NB) is the most common malignant tumour in
infants and the fourth most common malignancy in children older
than 1 year of age (Brodeur and Maris, 2001). Neuroblastoma may
regress spontaneously in infants, mature to benign ganglio-
neuromas in older children, or grow relentlessly and be rapidly
fatal (Brodeur and Maris, 2001). In NB, angiogenesis appears to
play an important role in determining tumour phenotype (Ribatti
et al, 2004). A spectrum of angiogenesis stimulators, such as
vascular endothelial growth factor and fibroblast growth factor-2
(FGF-2), as well as inhibitors, such as tissue inhibitors of matrix
metalloproteinases (MMP), have been detected in NB tumours
(Ara et al, 1998; Meister et al, 1999; Eggert et al, 2000). Moreover,
increased production of MMP-2 and -9 has been observed in
advanced disease stages, favouring degradation of extracellular
matrix and enhancing tumour dissemination (Ara et al, 1998;
Sugiura et al, 1998; Sakakibara et al, 1999; Ribatti et al, 2001b).
High tumour vascularity correlates with metastatic disease, MYC
amplification, unfavourable histology and poor outcome; by
contrast, low tumour vascularity is associated with favourable
prognostic features, such as localised disease and favourable
histology (Meitar et al, 1996; Canete et al, 2000; Katzenstein et al,
2000; Ribatti et al, 2002).
Thus, inhibition of angiogenesis may represent a useful
approach for adjuvant therapy (Ribatti and Ponzoni, 2005) in
metastatic NB patients, whose survival is poor (Maris and Matthay,
1999). However, evaluation of efficacy of potential angiogenic
inhibitors requires a better understanding of the in vivo angiogenic
potential of NB cells and of their contribution to vasculogenic
mimicry (Folberg and Mantiotis, 2004). Endothelial cells showing
the same genetic alteration as tumour cells have recently been
found in human tumours (Gunsilius, 2003; Hida et al, 2004;
Streubel et al, 2004), supporting the hypothesis that this could be a
general phenomenon.
To address these questions, we took advantage of the highly
angiogenic phenotype of the human NB cell line ACN in
immunodeficient mice (Corrias et al, 1998). Parental and vector-
transfected ACN xenografts showed numerous blood vessels and a
well-defined vascularisation in the small fibrous bands lining the
tumour cell nests (Corrias et al, 1998; Airoldi et al, 2004). By
contrast, human interferon-g (IFN-g) transfectans showed focal
basement membrane destruction and alterations in the micro-
vascular architecture, thereby supporting the hypothesis that IFN-g
could affect the angiogenic potential of NB cells besides reducing
tumour cell proliferation (Airoldi et al, 2004). Antiangiogenic
effects of IFN-g, in fact, have been described in humans as well
as in several in vitro and in vivo models. Precisely, murine
IFN-g produced by either CD4þ or CD8þ cells inhibits
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stumour-induced angiogenesis in syngeneic tumour models (Saiki
et al, 1992; Qin and Blankenstein, 2000; Blankenstein and Qin,
2003). Human IFN-g inhibits proliferation and migration of human
endothelial cells and capillary tube formation in vitro (Brouty-
Boye and Zetter, 1980; Friesel et al, 1987; Tsuruoka et al, 1988;
Maheshwari et al, 1991; Albini et al, 2000) and represses
lymphocyte-induced tumour angiogenesis (Sidky and Borden,
1987).
Here, using the chick embryo chorioallantoic membrane (CAM)
assay (Ribatti et al, 2001a), we show that the ACN/IFN-g xenografts
have a lower microvessel density and decreased angiogenic
potential in vivo compared to vector-transfected ACN/neo cells.
Moreover, the antiangiogenic activity of ACN/IFN-g xenografts
affected vascular channels by increasing apoptosis of both murine
and human endothelial cells, likely through nitric oxide (NO)
production.
MATERIALS AND METHODS
Human IFN-c-transfected cell line
The NB cell line ACN was stably transfected with a human IFN-g
cDNA cloned in the XbaI blunted-BamHI sites of plasmid RSV.5
neo (later referred as ACN/IFN-g) or with the empty vector (later
referred as ACN/neo) (Airoldi et al, 2004).
Nude mice studies
Pathogen-free female athymic (nu/nu) mice, 6–8 weeks old,
were obtained from Harlan Italy (San Pietro al Natisone, Italy).
Animal experiments, performed according to the National
Regulation on Animal Research, were approved by the Review
Board of the Istituto Nazionale per la Ricerca sul Cancro (Genoa,
Italy). Mice were housed under sterile conditions and received
autoclaved food and water. Animals (10 for each group) were
injected subcutaneously with 2 10
7 ACN/neo or ACN/IFN-g cells.
Tumours were removed on days 8, 14 and 28 post injection (p.i.)
and fixed either in 4% paraformaldehyde or Bouin’s solution. For
CAM experiments, tumours were removed on day 28 and snap-
frozen in liquid nitrogen and stored at  801C until tests were
performed.
Immunohistochemical study
After fixation, ACN/neo and ACN/IFN-g tumours were embedded
in paraffin, sectioned at 4mm and stained with haematoxylin–
eosin for histological evaluation. For immunohistochemistry,
a murine monoclonal antibody (mAb) against murine CD31
(clone 1A10, Dako, Glostrup, Denmark), a more sensitive
endothelial cell marker than factor VIII antigen (Horak et al,
1992), was used. Briefly, sections were collected on 3-amino-
propyl-triethoxysilane-coated slides, deparaffinised by the
xylene–ethanol sequence, rehydrated in a graded ethanol scale
and in Tris-buffered saline (TBS, pH 7.6) and incubated overnight
at 41C with the mAb 1A10 (1:25 in TBS), after antigen retrieval by
enzymatic digestion with Ficin (Sigma, St Louis, MO, USA) for
30min at room temperature. Immunodetection was performed
with alkaline phosphatase anti-alkaline phosphatase (Dako) and
Fast Red as chromogen, followed by haematoxylin counterstaining.
Negative control was an unrelated monoclonal IgG1 produced by
the P3X63/Ag8 mouse secretory myeloma (Vacca et al, 1993). For
CXCL10 and CXCL9 expression studies, sections were incubated
with an anti-human CXCL10 (IP10) mAb (ab8098, Abcam Ltd,
Cambridge, UK) and an anti-human CXCL9 (Mig) polyclonal
antibody (500-P50, Tebu-Bio, Combs, UK) and developed as
above.
Determination of microvessel area
These experiments were simultaneously and independently
performed by two investigators (DR and BN) using a computerised
image analysis system (Leica Quantimet 5000, Wetzlar, Germany).
Four to six  250 fields, covering almost entirely each of the three
sections tested (the third section of a series of three sections each
for a total of nine serial sections), per sample were examined with a
144-intersection-point square reticulum (0.0186mm
2field
 1 and
129.13mm
2point
 1) inserted in the eyepiece. Care was taken to
select microvessels, that is, capillaries and small venules, from all
the CD31-stained vessels. These vessels were identified as
transversally sectioned tubes with a single layer of endothelial
cells, without or with a lumen (diameter ranging from 3 to 10mm).
Each assessment was agreed upon in turn. Microvessels were
counted by a planimetric ‘point-count method’ (Elias and Hyde,
1983) with slight modifications, whereby only transversally cut
microvessels occupying the reticulum points were counted. As the
microvessel diameter was smaller than the distance between
adjacent points, only one transversally sectioned microvessel could
occupy a given point. Microvessels transversally sectioned outside
the points and those longitudinally or tangentially sectioned were
excluded. Thus, a given microvessel was counted only once, even
in the presence of several of its section planes. As nearly the entire
section of each of three non-adjacent sections per sample was
analysed, and as transversally sectioned microvessels hit the
intersection points randomly, the method allowed objective
counts. The microvessel area was then measured as the sum of
points that hit microvessels, and expressed as mean percentage71
s.d. for each section, sample and group of samples.
Immunofluorescence and fluorescence in situ
hybridisation analysis (FICTION)
In a preliminary set of experiments, endothelial cells were first
identified by immunofluorescence using a rat anti-mouse CD34
(Dako, clone MEC 14.7) and a mouse anti-human CD31 (Dako,
clone JC70A); a goat FITC-conjugated anti-rat (Dako) and an Alexa
Fluor
s rabbit anti-mouse (Invitrogen, Paisley, UK) antibody were
used as secondary reagents.
FICTION (fluorescence immunophenotyping and interphase
cytogenetics) experiments were performed on 4-mm-thick paraffin
sections of the tumour samples according to the previously
described protocol (Martinez-Ramirez et al, 2004). Precisely, in a
second set of experiments, immunofluorescence was performed
either with the anti-mouse CD34 or the anti-human CD31, which
were respectively developed with a goat FITC-conjugated anti-rat
or with a rabbit FITC-conjugated anti-mouse antibody, from Dako,
according to Weber-Matthiesen et al (1992). After immunostain-
ing, which stained endothelial cells in green, fluorescence in situ
hybridisation (FISH) was performed using either the TRITC-
labelled centromeric probe specific for the human chromosome 1
(Qbiogene, Illkirch, Cedex, France) or a mouse Cot1-DNA
(Invitrogen) labelled with Spectrum Orange deoxyuridine triphos-
phate using a nick translation kit according to the manufacturer’s
instructions (Vysis, Downers Grove, IL, USA). Afterwards, slides
were washed and mounted in antifade solution with DAPI
(Vectashield, Vector Burlingame, CA, USA). Images were captured
using a Nikon Eclipse E1000 epifluorescence microscope (Nikon
Corp., Tokyo, Japan) equipped with filter sets for DAPI (nuclei
counterstaining), FITC (immunofluorescence signals) and TRITC
(FISH signals).
Terminal deoxynucleotidyl transferase-mediated dUTP
nick end labelling assay
DNA cleavage was assessed by enzymatic end-labelling of DNA
strand breaks using a commercial kit (In Situ Cell Death Detection
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sKit; Roche, Penzberg, Germany) according to the manufacturer’s
instructions. Briefly, deparaffinised slides with sections of ACN/
IFN-g or ACN/neo xenografts were washed in phosphate-buffered
saline (PBS) and permeabilised with 0.1% Triton X-100 and 0.1%
sodium citrate for 2min at 41C; after rinsing, slides were incubated
with 50ml of terminal deoxynucleotidyl transferase (TdT)-
mediated dUTP nick end labelling (TUNEL) reaction mixture,
containing TdT- and FITC-labelled dUTP, in a humidified
atmosphere for 1h at 371C in the dark. Afterwards, slides were
rinsed and immunofluorescence was performed as described above
with either anti-human CD31 or anti-mouse CD34, developed with
a goat PE-conjugated anti-rat (Dako) and a rabbit PE-conjugated
anti-mouse (Dako) antibody, respectively. Rinsed slides were then
mounted in antifade solution with DAPI and images were captured
as above with filter sets for DAPI (nuclei counterstaining), FITC
(TUNEL) and TRITC (immunofluorescence). The percentages of
apoptotic human and murine endothelial cells was calculated by
dividing the TUNEL-positive CD31þ or CD34þ cells, respec-
tively, by the total number of CD31þ or CD34þ cells counted in
two slides for each assay. A Kruskal–Wallis test was then
performed to assess statistical significance.
Nitrate assay
NO production was evaluated as NO2 accumulation (Melillo et al,
1996). Briefly, cell-free supernatants of 48h culture of ACN/IFN-g
or ACN/neo cells were incubated with the Griess reagent for 10min
at room temperature in triplicate and the absorbance measured
in a 96-well plate reader (SPECTRAfluor Plus, TECAN,
Grodig, Austria) at 550nm. The concentration was determined
through a sodium nitrite standard curve. The limit of sensitivity
was 1.5mM.
Chorioallantoic membrane assay
Fertilised White Leghorn chicken eggs (20 for each series) were
incubated at 371C at constant humidity. On the third incubation
day, a square window was opened in the eggshell after removal of
2–3ml of albumen to detach the developing CAM from the shell.
The window was sealed with a glass and the eggs were returned to
the incubator. On day 8, CAM were implanted, under sterile
conditions within a laminar flow hood, with 1mm
3 sterilised
gelatin sponges (Gelfoam; Upjohn Co., Kalamazoo, MI, USA)
(Ribatti et al, 1997). Sponges were loaded with 1ml PBS or with
500ng human recombinant FGF-2 (R&D Systems, Minneapolis,
MN, USA) as negative and positive controls, respectively. Snap-
frozen ACN/neo and ACN/IFN-g tumours were minced in sterile
RPMI 1640 to obtain 1–2mm
3 fragments, which were grafted onto
the CAM of chick embryos on day 8, as previously described
(Ribatti et al, 2002). Care was taken to select necrosis- and
bleeding-free fragments. The CAM were examined daily until day
12 and photographed in ovo with a stereomicroscope equipped
with an MC 63 Camera System (Zeiss, Oberkochen, Germany). On
incubation day 12, when the angiogenic response peaked, blood
vessels entering the implant within the focal plane of the CAM
were recognised macroscopically, counted at  50 magnification
by two observers (DR and BN) in a double-blind fashion with a
stereomicroscope and photographed. Mean values 71 s.d. for
vessel count were determined for each analysis. The CAM were
also processed for light microscopy. Serial sections (8mm) were cut
in a plane parallel to the surface of the CAM, stained with a 0.5%
acqueous solution of toluidine blue (Merck, Darmstadt, Germany)
and observed under a Leitz-Dialux 20 light photomicroscope
(Leitz, Wetzlar, Germany). Some sections were also stained using
the mAb anti-CD31 and the microvessel area inside the tumour
xenografts was evaluated as described above.
Statistics
Statistical significance of differences observed between the
experimental (ACN/IFN-g) and control (ACN/neo) groups was
determined using the Student’s t-test for unpaired data. Statistical
significance of differences in apoptosis of human and murine
endothelial cells in ACN/IFN-g and ACN/neo xenografts was
determined by means of the non-parametric Kruskal–Wallis test.
RESULTS
Histopathological features and microvascular area of ACN
xenografts
As opposed to parental and vector-transfected ACN xenografts
showing numerous blood vessels and a well-defined vascularisa-
tion (Corrias et al, 1998), ACN/IFN-g xenografts are characterised
by extensive necrotic areas and focal basement membrane
destruction (Airoldi et al, 2004). We thus evaluated the size of
the microvessel area in the ACN/IFN-g and ACN/neo xenografts.
Tumours removed on day 14 p.i. and stained with anti-CD31,
which selectively identifies microvessels and their long off shots
reaching into the stroma, are shown in Figure 1A and B,
respectively (microvessel density¼3.5% for ACN/neo vs 11.2%
for ACN/IFN-g xenografts, Po0.001). Microvessel areas were
significantly smaller in ACN/IFN-g than in ACN/neo specimens at
any time tested.
A
B
Figure 1 Immunohistochemical analysis of ACN/neo (A) and ACN/IFN-g
(B) tumours removed 14 days after injection. The microvessel density,
determined by means of an anti-CD31 antibody recognising endothelial
cells, was significantly (Po0.001) higher in ACN/neo than in ACN/IFN-g
tumours. Original magnification:  160.
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sCharacterisation of tumour endothelium in ACN
xenografts by FICTION
As microvascular endothelial cells may exhibit the same genetic
aberrations as tumour cells (Gunsilius, 2003; Hida et al, 2004;
Streubel et al, 2004), we first analysed whether the tumour
vasculature in ACN/neo and ACN/IFN-g xenografts contained
tumour-derived endothelial cells. As shown in Figure 2A, micro-
vessels of both human and murine origin were found in both
xenografts. Quite interestingly, individual microvessels composed
of both human and murine cells were observed (Figure 2B). Next,
we applied the FICTION technique to confirm that the human
endothelial cells were derived from the tumour cells. In fact, using
this technique, which combines immunofluorescence and FISH
(Weber-Matthiesen et al, 1992), it is possible to identify a given cell
type, detected by mAb staining, on the basis of specific genetic
profile.
Thus, after immunofluorescence performed using either anti-
human CD31 or anti-mouse CD34 and FITC-conjugated secondary
reagents, slides were hybridised to a mouse Cot1-DNA or to a
centromere-specific human chromosome 1 probe that were
labelled in red. ACN cells did not hybridise to the Cot-1 probe
(Figure 3A), whereas murine cells showed large red fluorescent
signals (Figure 3A, inset). The same hydridisation signals were
evident in CD34-positive endothelial cells (Figure 3B), confirming
their murine origin.
Conversely, the centromere-specific human chromosome 1
probe hybridised to human (Figure 3C) but not murine
(Figure 3C, upper inset) metaphases. ACN cells showed several
signals (Figure 3C, lower inset) indicative of chromosome 1
aneuploidy. After hybridisation with the centromere-specific
human chromosome 1 probe, CD31-positive endothelial cells
(Figure 3D) showed the same pattern as tumour cells, thereby
demonstrating that endothelial cells of human origin were indeed
derived from the human tumour cells.
Although the absolute number of murine microvessels was lower
in ACN/IFN-g xenografts than in ACN/neo xenografts, their
percentages were similar in both tumours (7074 vs 6973, three
serial sections for each xenograft), indicating that the ratio
between murine and human vessels (approximately 2:1) was
unaffected by IFN-g.
Interferon-c released by transfected cells induced
apoptosis of endothelial cells
In order to elucidate the mechanism(s) by which the released IFN-
g inhibited angiogenesis, the expression of the known antiangio-
genic, IFN-g-induced, human CXCL10 and CXCL9 proteins was
analysed in both ACN/IFN-g and ACN/neo xenografts. As neither
protein was detected (data not shown), we checked whether
apoptosis of endothelial cells occurred in the ACN/IFN-g
xenografts rather than the ACN/neo xenografts, by means of the
TUNEL assay. Cells positive for TUNEL were then identified by
immunofluorescence using either anti-murine CD34 or anti-
human CD31 mAbs. Whereas in the ACN/IFN-g xenografts, both
murine and human endothelial cells were TUNEL-positive (7573
and 5273%, Figure 4A and B, respectively), no apoptosis of either
murine- or human-derived endothelial cells was observed in ACN/
neo xenografts (271 and 373%, Figure 4C and D, respectively).
The difference in apoptotic cells between ACN/IFN-g and ACN/neo
xenografts was significant (P¼0.002) regardless of the murine or
human nature of the endothelial cells. In the ACN/IFN-g xenograft,
the proportion of TUNEL-positive murine endothelial cells was
higher (P¼0.002) than that of human-derived endothelial cells.
To investigate the possible mediator of the apoptotic signal
affecting both murine and human endothelial cells, production of
NO was measured in the supernatants from ACN/IFN-g and ACN/
neo cells cultured in vitro. The ACN/IFN-g supernatants contained
about 10mM NO, whereas no detectable NO was found in the ACN/
neo supernatants (Po0.05).
Inhibition of CAM vascularisation by sponges treated with
ACN/IFN-c tumours
To further evaluate the in vivo angiostatic activity of human IFN-g
released by transfected cells, CAM vascularisation assays were
performed (Ribatti et al, 1997). Gelatin sponges treated with
hrFGF-2 (positive control) were surrounded by allantoic vessels
that developed radially in a ‘spoked wheel’ pattern towards them
(Figure 5A). Microscopically, a highly vascularised tissue was
recognisable among the sponge trabeculae as newly formed blood
vessels within an abundant network of collagen fibres (Figure 5B).
When the sponges were loaded with PBS (negative control),
physiological angiogenesis was observed in the form of some
allantoic vessels partly arranged around the sponge (not shown).
Microscopically, there were no blood vessels among the sponge
trabeculae (not shown).
When the CAM assay was performed using ACN/IFN-g or ACN/
neo tumour xenografts, the number of vessels macroscopically
counted around the implant was significantly lower in ACN/IFN-g
than in ACN/neo biopsies (1573 vs 3474, Po0.001, as shown in
Figure 5C and E, respectively). Microscopically, the CAM area
away from the implant was made up of a surface epithelium arising
from the ectoderm (chorion), an intermediate mesenchyme
containing arterious and venous vessels merging with a capillary
network running under the chorion and a deep epithelium arising
from the ectoderm (allantois). Tumour implants adhered to the
A
B
Figure 2 Immunofluorescence performed on ACN/IFN-g paraffin-
embedded sections. (A) Section simultaneously incubated with a rat anti-
mouse CD34 and a mouse anti-human CD31 antibody developed,
respectively, with a goat FITC-conjugated anti-rat and an Alexa Fluor
s
rabbit anti-mouse (human CD31 positive: red; murine CD34 positive:
green). Original magnification:  1000. (B) Section incubated as in (A)
where a microvessel composed of both red and green cells is shown.
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schorion without invading the mesenchyme. The CAM vessels were
arranged radially beneath the implants, and were less numerous in
ACN/IFN-g than in ACN/neo xenografts. A significant (Po0.001)
decrease in microvessel area (1.2%; Figure 5D), evaluated as CD31-
positive area, was detected in ACN/IFN-g xenografts compared to
ACN/neo grafts (5.8%; Figure 5F).
DISCUSSION
Inhibitors of angiogenesis block any of the several steps in the
angiogenic cascade, including proliferation and attachment of
endothelial cells to the extracellular matrix proteins, as well as
migration and invasion through the matrix (Bikfalvi and Bicknell,
AB
CD
Figure 3 FICTION analysis of ACN/IFN-g paraffin-embedded sections. (A) ACN/IFN-g sections hybridised with the murine Cot-1 probe. The murine cell
line TAP-1 hybridised with the Cot-1 probe is shown in the inset. (B) Identification of microvessel of mouse origin with anti-mouse CD34 (green) and a
Cot-1 probe (red). (C) Human metaphase hybridised with the centromere-specific human chromosome 1 probe (red). Murine metaphase hybridised with
the same probe is shown in the upper inset. ACN cells hybridised with the same probe are shown in the lower inset. (D) Identification of microvessels of
human origin with anti-human CD31 (green) and the centromere-specific human chromosome 1 probe (red). Original magnification: (A)  200, (B–D)
 1000.
Figure 4 Immunofluorescence and TUNEL assay. ACN/IFN-g (A, B) and ACN/neo (C, D) deparaffinized sections were subject to TUNEL assay (green)
and then stained by immunofluorescence in red using either anti-murine CD34 (A, C) or anti-human CD31 (B, D) mAbs. Colocalisation of red and green
(yellow) indicated apoptosis of endothelial cells. Original magnification: (A–D)  1000.
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s2002). Here, we show that IFN-g transfection of human NB cells
exploited an antiangiogenic effect, measured by the lower
microvessel density and the lower angiogenic potential in CAM
assay of ACN/IFN-g xenografts with respect to vector-transfected
ACN/neo xenografts. Thus, human IFN-g can affect NB tumour
growth by inhibiting both tumour angiogenesis and proliferation
(Airoldi et al, 2004). Two types of endothelial microvessels were
detected in ACN xenografts, one being of murine origin and the
other deriving from human tumour cells. Finally, in the ACN/IFN-g
xenografts, a high percentage of apoptotic murine and human
endothelial cells were detected.
Transfection of human IFN-g in other tumour cell types already
suggested that IFN-g inhibited angiogenesis. The acquired
immunity against IFN-g-transfected RT2 glioma cells was postu-
lated to be primarily caused by the antiangiogenic activity of
the secreted cytokine (Fathallah-Shaykh et al, 1998). Qin and
Blankenstein (2000) and Qin et al (2003) showed that rejection of
different tumours by CD8þ T cells was always preceded by
inhibition of tumour-induced angiogenesis. Moreover, in some
murine models, the antiangiogenic activity mediated by IL-12 and
IL-18 was shown to be IFN-g mediated (Voest et al, 1995; Cao et al,
1999), and inhibition of angiogenesis by IFN-g was found to occur
in colon carcinoma through transcriptional silencing of perlecan
gene expression (Sharma and Iozzo, 1998).
The antiangiogenic effect observed in the ACN/IFN-g xenografts
was not mediated by the CXCL9 and CXCL10 proteins, a finding
that contrasts with results from other tumour models (Strieter
et al, 1995, Sgadari et al, 1996, Pertl et al, 2001) and with our
previous observation that CXCL10 (IP-10) mRNA was induced in
IFN-g-transfected ACN cells (Airoldi et al, 2004). The antiangio-
genic effect was mainly due to apoptosis of both murine- and
tumour-derived endothelial cells, reflecting previous findings in
IFN-g-transfected brain tumour cells (Fathallah-Shaykh et al,
2000). The p38 MAPK/Stat1/IRF-1 pathway (Wang et al, 1999;
Huang et al, 2002; Lee et al, 2005), cathepsin B (Li and Pober,
2005), Fas/FasL interaction (Li et al, 2002), integrin function
(Ruegg et al, 1998) and NO production (Yamaoka et al, 2002;
Vekemans et al, 2004; Lee et al, 2005) have been shown to drive
IFN-g-dependent apoptosis of endothelial cells. As not only human
but also murine endothelial cells in ACN/IFN-g xenografts were
TUNEL-positive, neither the released human IFN-g nor other
species-specific mediators could be involved in mediating
apoptosis in our model. Moreover, absence of FasL expression in
the ACN and ACN/IFN-g cells (not shown), and lack of infiltrating
lymphocytes in the xenografts, excluded involvement of the Fas/
FasL axis, at variance with other models (Sidky and Borden, 1987;
Saiki et al, 1992). The demonstration that the ACN/IFN-g cells
produced NO strongly supported its role in driving the apoptotic
signal to the endothelial cells. In this view, it is conceivable that
a non-species-specific mediator, like NO, was responsible for
inhibition of angiogenesis observed in other human IFN-trans-
fected tumour cells growing in athymic mice (Hock et al, 1993;
Fathallah-Shaykh et al, 2000; Ozawa et al, 2001; Izawa et al, 2002;
Qin et al, 2002).
In ACN/IFN-g xenografts, the proportion of apoptotic murine
was higher than that of human endothelial cells, whereas their
relative ratio remained unaltered (2:1). These findings support the
hypothesis that the antiangiogenic effect of IFN-g on human
endothelial cells required other mechanisms besides apoptosis.
Human IFN-g inhibits endothelial migration and proliferation
(Brouty-Boye and Zetter, 1980; Friesel et al, 1987; Tsuruoka et al,
1988; Albini et al, 2000) and has strong antiproliferative effects on
NB tumour cells (Ponzoni et al, 1992; Airoldi et al, 2004), from
which the human endothelial cells derived. Thus, the antiangio-
genic effect was likely due to a combination of apoptosis and
reduced proliferation. In this regard, it is of note that whereas
apoptosis of tumour-derived endothelial cells was high, that of the
tumour cells themselves was negligible, suggesting that transdif-
ferentiation of ACN tumour cells into endothelial cells was
accompanied by pathway changes.
The remarkable inhibition of angiogenesis by IFN-g-transfected
NB cells reported here, together with our preliminary observation
that human recombinant IFN-g reduced vessel growth induced by
exogenous FGF-2 in the CAM assay by 80% (data not shown),
lends additional support to the concept that angiogenesis
inhibition is part of the general mechanism of action of IFN-g.
The possibility that this cytokine can find a place as an angiostatic
adjuvant in the treatment of unresponsive NB, whose survival is
poor (Maris and Matthay, 1999), warrants further investigation.
In conclusion, our study demonstrates an antiangiogenic effect
of IFN-g through the induction of apoptosis of both murine- and
tumour-derived endothelial cells, likely mediated by NO produc-
tion. Thus, should the contribution of tumour cell-derived
microvessels be confirmed in human NB primary tumours, as
our preliminary findings with MYCN amplified NB tumours seem
to indicate (Pezzolo et al, unpublished), NB xenografts made up of
mixed murine- and tumour-derived endothelial cells may prove
useful for the testing of the therapeutic activity of antiangiogenic
compounds.
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Figure 5 (A) A 12-day-old chick embryo CAM incubated on day 8 for 4
days with a gelatin sponge loaded with 500ng hrFGF-2. Note numerous
allantoic blood vessels with a radially arranged ‘spoked wheel’ pattern
around the sponge. (B) Histological section of the sponge shown in (A).
Note numerous small blood vessels among the sponge trabeculae
intermingled with a collagenous matrix. (C) A 12-day-old CAM incubated
on day 8 for 4 days with bioptic specimen of ACN/IFN-g tumour xenograft,
showing few vessels around the graft. (D) Immunohistochemical analysis of
the xenograft, showing few CD31-positive blood vessels. (E) A 12-day-old
CAM incubated on day 8 for 4 days with bioptic specimen of ACN/neo
tumour xenograft, showing numerous blood vessels around the graft. (F)
Immunohistochemical analysis of the xenograft, showing numerous CD31-
positive blood vessels. The microvessel density, determined by means of an
anti-CD31 antibody recognising endothelial cells, is significantly (Po0.001)
lower in ACN/IFN-g than in ACN/neo xenografts. Original magnification:
(A, C, E)  50; (B, D, F)  400.
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